[go: up one dir, main page]

PE20010053A1 - Formulacion de amoxicilina y clavulanato de potasio - Google Patents

Formulacion de amoxicilina y clavulanato de potasio

Info

Publication number
PE20010053A1
PE20010053A1 PE2000000332A PE0003322000A PE20010053A1 PE 20010053 A1 PE20010053 A1 PE 20010053A1 PE 2000000332 A PE2000000332 A PE 2000000332A PE 0003322000 A PE0003322000 A PE 0003322000A PE 20010053 A1 PE20010053 A1 PE 20010053A1
Authority
PE
Peru
Prior art keywords
amoxicillin
clavulanate
plasma
refers
potassium clavulanate
Prior art date
Application number
PE2000000332A
Other languages
English (en)
Inventor
Creighton Conley
Kevin Storm
John Roush
Original Assignee
Beecham Pharm Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27383840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20010053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Pharm Pte Ltd filed Critical Beecham Pharm Pte Ltd
Publication of PE20010053A1 publication Critical patent/PE20010053A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE AL USO DE 1900 mg A 2600 mg DE AMOXICILINA Y CLAVULANATO DE POTASIO SE CARACTERIZA POR LA RELACION EN PESO DE AMOXICILINA A CLAVULANATO DE 2:1 A 20:1, DE PREFERENCIA 2000/125 mg, 2250/125 mg, 2500/125 mg A INTERVALOS DE ALREDEDOR DE 12 h; POR LA CONCENTRACION MEDIA DE AMOXICILINA EN EL PLASMA DE 4µg/ml DURANTE AL MENOS 4,4 h Y UNA CONCENTRACION MAXIMA MEDIA DE AMOXICILINA EN EL PLASMA DE AL MENOS 16 µg/ml; TAMBIEN SE REFIERE A UNA FORMULACION DE LIBERACION MODIFICADA EN LA QUE EL CLAVULANATO ES LIBERADO INMEDIATAMENTE Y UNA PRIMERA PARTE DE LA AMOXICILINA SE FORMULA CON EXCIPIENTES QUE PERMITEN LA LIBERACION INMEDIATA; UNA SEGUNDA PARTE QUE PERMITE LA LIBERACION LENTA DE AMOXICILINA (AMOXICILINA DE SODIO CRISTALIZADA) QUE SE CARACTERIZA PORQUE LA CAPA DE LIBERACION LENTA COMPRENDE UN EXCIPIENTE QUE PUEDE SER UN POLIMERO TAL COMO GOMA XANTANA, ENTRE OTROS, O UN ACIDO ORGANICO TAL COMO ACIDO CITRICO; EL QUE RETARDA LA LIBERACION; ES SENSIBLE AL pH; Y TIENE ALTO GRADO DE HINCHAMIENTO EN CONTACTO CON AGUA
PE2000000332A 1999-04-13 2000-04-11 Formulacion de amoxicilina y clavulanato de potasio PE20010053A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12907499P 1999-04-13 1999-04-13
US15072799P 1999-08-25 1999-08-25
US15981399P 1999-10-15 1999-10-15

Publications (1)

Publication Number Publication Date
PE20010053A1 true PE20010053A1 (es) 2001-03-10

Family

ID=27383840

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000332A PE20010053A1 (es) 1999-04-13 2000-04-11 Formulacion de amoxicilina y clavulanato de potasio

Country Status (45)

Country Link
EP (4) EP1269996A1 (es)
JP (2) JP4880125B2 (es)
KR (1) KR100634937B1 (es)
CN (1) CN100382782C (es)
AP (1) AP1806A (es)
AR (1) AR031068A1 (es)
AT (2) AT4327U1 (es)
AU (1) AU767177B2 (es)
BE (2) BE1012733A6 (es)
BG (1) BG65006B1 (es)
BR (1) BRPI0009719B8 (es)
CA (1) CA2366304C (es)
CO (1) CO5170471A1 (es)
CZ (1) CZ298801B6 (es)
DE (3) DE20006626U1 (es)
DK (3) DK1044680T3 (es)
DZ (1) DZ3150A1 (es)
EA (1) EA004310B1 (es)
ES (2) ES2190692B1 (es)
FI (2) FI4823U1 (es)
FR (1) FR2792198A1 (es)
GB (1) GB2351661B (es)
GR (1) GR1003560B (es)
HK (1) HK1032741A1 (es)
HU (1) HU229097B1 (es)
IE (1) IE20000271A1 (es)
IL (2) IL145580A0 (es)
IT (1) ITMI20000788A1 (es)
MA (1) MA25352A1 (es)
MX (1) MXPA01010377A (es)
MY (1) MY119953A (es)
NL (2) NL1014914C1 (es)
NO (1) NO329694B1 (es)
NZ (1) NZ514575A (es)
OA (1) OA11926A (es)
PE (1) PE20010053A1 (es)
PL (1) PL197448B1 (es)
PT (2) PT102450B (es)
RO (1) RO120817B1 (es)
SE (1) SE0001330L (es)
SI (2) SI20304A (es)
SK (1) SK285140B6 (es)
TR (1) TR200102963T2 (es)
TW (1) TWI235067B (es)
WO (1) WO2000061116A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
CN1289084C (zh) * 1995-09-07 2006-12-13 史密丝克莱恩比彻姆有限公司 药物制剂
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
WO2002030392A2 (en) * 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
CA2452874A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
CA2481486C (en) * 2002-04-10 2012-06-12 Fred H. Miller Multi-phase, multi-compartment capsular system
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1541129A1 (en) * 2003-12-12 2005-06-15 Cimex AG Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid
EP1750717B1 (en) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2005099672A1 (en) * 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
EP1880716A1 (en) * 2006-07-19 2008-01-23 Sandoz AG Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
CN101578096A (zh) * 2006-10-10 2009-11-11 潘威斯脱药物公司 稳健的缓释制剂
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
AU2016246583B2 (en) 2015-04-07 2020-06-25 Church & Dwight Co., Inc. Multicomponent gummy compositions with soft core
CN109394718B (zh) * 2018-11-15 2021-04-27 石药集团中诺药业（石家庄）有限公司 一种阿莫西林分散片及其制备方法
CN110051637A (zh) * 2019-05-21 2019-07-26 葵花药业集团北京药物研究院有限公司 阿莫西林克拉维酸钾制剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008905B1 (en) * 1978-09-06 1983-02-16 Beecham Group Plc Pharmaceutical compositions containing two beta-lactam derivatives
IL58461A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
AU5863894A (en) * 1993-01-22 1994-08-15 Smithkline Beecham Plc Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
GB9311030D0 (en) * 1993-05-28 1993-07-14 Smithkline Beecham Corp Pharmaceutical formulations
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
ITMI941169A1 (it) * 1994-06-06 1995-12-06 Smithkline Beecham Farma Formulazioni farmaceutiche
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
CN1289084C (zh) * 1995-09-07 2006-12-13 史密丝克莱恩比彻姆有限公司 药物制剂
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
WO1998035672A1 (en) * 1997-02-14 1998-08-20 Smithkline Beecham Laboratoires Pharmaceutiques Pharmaceutical formulations comprising amoxocyllin and clavulanate
WO1998040541A1 (en) * 1997-03-11 1998-09-17 Almag Al Process and apparatus for coating metals
SE9700885D0 (sv) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
KR20000076329A (ko) * 1997-03-25 2000-12-26 다케다 야쿠힌 고교 가부시키가이샤 위장 점막 부착성 약제 조성물
JP3746901B2 (ja) * 1997-10-15 2006-02-22 ユニ・チャーム株式会社 開閉自在容器
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
GB9818927D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Pharmaceutical formulation
US6225304B1 (en) * 1999-02-17 2001-05-01 Pharmaceutical Solutions, Inc. Soluble forms of amoxicillin and treatment of animals

Also Published As

Publication number Publication date
FI20000863A0 (fi) 2000-04-11
ES2190692A1 (es) 2003-08-01
BG104329A (en) 2001-11-30
NO329694B1 (no) 2010-12-06
KR100634937B1 (ko) 2006-10-17
NZ514575A (en) 2004-05-28
PT1044680E (pt) 2003-10-31
SI1044680T1 (en) 2003-12-31
AP1806A (en) 2007-12-14
NL1014915C2 (nl) 2001-02-12
ES2190692B1 (es) 2004-11-16
GR1003560B (el) 2001-03-16
BG65006B1 (bg) 2006-12-29
AU767177B2 (en) 2003-11-06
PT102450B (pt) 2003-09-30
SE0001330L (sv) 2000-10-14
TR200102963T2 (tr) 2002-02-21
EP1270005A3 (en) 2006-05-17
HUP0001471A3 (en) 2001-10-29
ATE242629T1 (de) 2003-06-15
GB2351661B (en) 2001-10-10
FIU20000164U0 (fi) 2000-04-11
WO2000061116A3 (en) 2001-02-01
ITMI20000788A1 (it) 2001-10-11
JP4880125B2 (ja) 2012-02-22
EP1044680B1 (en) 2003-06-11
CA2366304A1 (en) 2000-10-19
AT4327U1 (de) 2001-06-25
BE1013309A5 (fr) 2001-11-06
FI4823U1 (fi) 2001-02-16
DE20006626U1 (de) 2000-10-19
EA004310B1 (ru) 2004-02-26
BE1012733A6 (fr) 2001-02-06
SK5342000A3 (en) 2000-11-07
MY119953A (en) 2005-08-30
DZ3150A1 (fr) 2000-10-19
HU0001471D0 (en) 2000-06-28
ITMI20000788A0 (it) 2000-04-11
CN100382782C (zh) 2008-04-23
PL339591A1 (en) 2000-10-23
RO120817B1 (ro) 2006-08-30
DK200000133U3 (da) 2000-07-28
EP1269997A1 (en) 2003-01-02
HUP0001471A2 (en) 2001-03-28
FR2792198A1 (fr) 2000-10-20
DE10017883A1 (de) 2000-10-26
NO20001870L (no) 2000-10-16
OA11926A (en) 2006-04-12
PL197448B1 (pl) 2008-03-31
SK285140B6 (sk) 2006-07-07
KR20020015312A (ko) 2002-02-27
EA200101075A1 (ru) 2002-04-25
CZ298801B6 (cs) 2008-02-06
NL1014914C1 (nl) 2000-10-16
AU5702000A (en) 2000-11-14
SI20304A (sl) 2001-02-28
SE0001330D0 (sv) 2000-04-11
NL1014915A1 (nl) 2000-10-16
ES2202004T3 (es) 2004-04-01
CZ20001311A3 (cs) 2000-11-15
EP1269996A1 (en) 2003-01-02
GB2351661A (en) 2001-01-10
CN1382040A (zh) 2002-11-27
HU229097B1 (en) 2013-07-29
CA2366304C (en) 2004-06-29
IL145580A0 (en) 2002-11-10
BR0009719B1 (pt) 2014-09-30
EP1270005A2 (en) 2003-01-02
BRPI0009719B8 (pt) 2021-05-25
AP2001002284A0 (en) 2001-12-31
TWI235067B (en) 2005-07-01
MXPA01010377A (es) 2002-10-23
JP2011256180A (ja) 2011-12-22
PT102450A (pt) 2001-02-01
JP2002541187A (ja) 2002-12-03
IE20000271A1 (en) 2001-04-04
WO2000061116A2 (en) 2000-10-19
EP1044680A1 (en) 2000-10-18
AR031068A1 (es) 2003-09-10
HK1032741A1 (en) 2001-08-03
IL145580A (en) 2007-05-15
MA25352A1 (fr) 2001-12-31
DE60003255D1 (de) 2003-07-17
NO20001870D0 (no) 2000-04-11
BR0009719A (pt) 2002-01-08
DK1044680T3 (da) 2003-09-29
DK200000602A (da) 2000-10-14
GB0008923D0 (en) 2000-05-31
FI20000863L (fi) 2000-10-13
CO5170471A1 (es) 2002-06-27
DE60003255T2 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
PE20010053A1 (es) Formulacion de amoxicilina y clavulanato de potasio
ES2094694B1 (es) Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
BR0112519A (pt) Derivados anticonvulsivantes úteis para prevenir o desenvolvimento de diabetes melito do tipo ii e sìndrome x
UY26496A1 (es) Composiciones farmacéuticas que proporcionan concentraciones potenciadas de fármaco
DE69925133D1 (de) Pyrrolobenzodiazepine
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
BR0210519A (pt) Composições farmacêuticas de adsorvatos de fármaco amorfo
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
DE59707812D1 (de) Opioidantagonisthaltige galenische formulierung
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
SV2002000250A (es) Formula de dosis de droga accionada por hidrogel ref. pc10818ajtb/bb
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
ES2147739T3 (es) Fosfonooximetil-eteres de derivados de taxano.
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
BRPI0413588A (pt) sistema de branqueamento de dentes, método de branqueamento da superfìcie de um dente, e, kit de branqueamento de dentes
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
SE0102843L (sv) Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod
AR021934A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
PA8523101A1 (es) Composicion de eletriptan en forma de particulas
ATE388960T1 (de) Glykopeptidderivate mit carboxysacchariden
DK1142573T3 (da) Farmaceutiske præparater omfattende faropenem-natrium og en diaminacetatforbindelse til forbedring af absorption i mave-tarm-kanalen

Legal Events

Date Code Title Description
FC Refusal